Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Regulation of in situ to invasive breast carcinoma transition.
Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, Richardson A, Violette S, Nikolskaya T, Nikolsky Y, Bauerlein EL, Hahn WC, Gelman RS, Allred C, Bissell MJ, Schnitt S, Polyak K. Hu M, et al. Among authors: violette s. Cancer Cell. 2008 May;13(5):394-406. doi: 10.1016/j.ccr.2008.03.007. Cancer Cell. 2008. PMID: 18455123 Free PMC article.
High expression of integrin β6 in association with the Rho-Rac pathway identifies a poor prognostic subgroup within HER2 amplified breast cancers.
Desai K, Nair MG, Prabhu JS, Vinod A, Korlimarla A, Rajarajan S, Aiyappa R, Kaluve RS, Alexander A, Hari PS, Mukherjee G, Kumar RV, Manjunath S, Correa M, Srinath BS, Patil S, Prasad MS, Gopinath KS, Rao RN, Violette SM, Weinreb PH, Sridhar TS. Desai K, et al. Among authors: violette sm. Cancer Med. 2016 Aug;5(8):2000-11. doi: 10.1002/cam4.756. Epub 2016 May 17. Cancer Med. 2016. PMID: 27184932 Free PMC article.
Therapeutic targeting of integrin αvβ6 in breast cancer.
Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AR, Haider S, Brouilette K, Saha A, Vallath S, Bowen R, Chelala C, Eccles D, Tapper WJ, Thompson AM, Quinlan P, Jordan L, Gillett C, Brentnall A, Violette S, Weinreb PH, Kendrew J, Barry ST, Hart IR, Jones JL, Marshall JF. Moore KM, et al. Among authors: violette s. J Natl Cancer Inst. 2014 Jun 28;106(8):dju169. doi: 10.1093/jnci/dju169. Print 2014 Aug. J Natl Cancer Inst. 2014. PMID: 24974129 Free PMC article.
Integrin αvβ6 promotes an osteolytic program in cancer cells by upregulating MMP2.
Dutta A, Li J, Lu H, Akech J, Pratap J, Wang T, Zerlanko BJ, FitzGerald TJ, Jiang Z, Birbe R, Wixted J, Violette SM, Stein JL, Stein GS, Lian JB, Languino LR. Dutta A, et al. Among authors: violette sm. Cancer Res. 2014 Mar 1;74(5):1598-608. doi: 10.1158/0008-5472.CAN-13-1796. Epub 2014 Jan 2. Cancer Res. 2014. PMID: 24385215 Free PMC article.
Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.
Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, Ngam-ek A, Zeng W, Allaire N, Perrin S, Xu X, Szeliga K, Wortham K, Kelly R, Bottiglio C, Ding J, Griffith L, Heaney G, Silverio E, Yang W, Jarpe M, Fawell S, Reff M, Carmillo A, Miatkowski K, Amatucci J, Crowell T, Prentice H, Meier W, Violette SM, Mackay F, Yang D, Hoffman R, Browning JL. Lukashev M, et al. Among authors: violette sm. Cancer Res. 2006 Oct 1;66(19):9617-24. doi: 10.1158/0008-5472.CAN-06-0217. Cancer Res. 2006. PMID: 17018619
Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.
Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, LePage DJ, Kelly R, Heaney G, Rayhorn P, Reid C, Simon KJ, Horan GS, Tao N, Gardner HA, Skelly MM, Gown AM, Thomas GJ, Weinreb PH, Fawell SE, Violette SM. Van Aarsen LA, et al. Among authors: violette sm. Cancer Res. 2008 Jan 15;68(2):561-70. doi: 10.1158/0008-5472.CAN-07-2307. Cancer Res. 2008. PMID: 18199553
96 results